Celiprolol is a β-adrenergic blocker characterized by selective blokade of β1 receptors and partial agonist activity at β2 receptors. This study was designed to evaluate the antihypertensive efficacy, metabolic effects and safety of celiprolol in patients with essential hypertension.

Celiprolol 200mg was administered once daily in 20 hypertensive Korean adults(9 males and 11 females) for ten weeks with dose titration every 2 weeks.

The supine blood pressure was decreased from 168.8±20.6/106.5÷12.0mmHg(mean÷S.D) to 131.2±12.8/88.2±7.9mmHg at the end treatment(P<0.05). Heart rate was not changed significantly throughout the period. Total cholesterol(TC) was decreased from 211.3±12.6mg/dl to 186.7±10.4mg/dl(P<0.05) and triglyceride(TG) from 223.7±24.5mg/dl to 198.4±12.9mg/dl after 10 weeks treatment(P<0.05). LDL(low-density lipoprotein)-cholesterol was decreased from 126.4±13.4mg/dl to 118.5±12.3mg/dl after 10 weeks treatment(P<0.05). During the period of the study, headache and fatigue developed in a few patient but were not troublesome enough to stop medication.

Celiprolol 200mg once daily regimen was well tolerated and effective in the treatment of essential hypertensiove patients with favorable effects on blood lipids.